Plitidepsin

Apr 28, 2020

PharmaMar Has Announced That the Spanish Medicines Agency Has Authorized the APLICOV-PC Clinical Trial With Aplidin® (Plitidepsin) for the Treatment of Patients With COVID-19

Jun 26, 2018

PharmaMar and Chugai Agree to Terms for Early Termination of the License Agreement for Zepsyre® in Japan

Feb 14, 2018

PharmaMar Licenses Fully Synthetic Marine-derived Payloads to Seattle Genetics for Use in Drug Conjugates

Jan 03, 2018

PharmaMar has Requested the Process of Re-Examination for Aplidin® from the EMA

Jan 02, 2018

PharmaMar Signs a Commercialization and Distribution License Agreement for Aplidin® (plitidepsin) With Megapharm in Israel

Nov 15, 2017

Phase III Trial With Zepsyre® in Small-Cell Lung Cancer (ATLANTIS) to Continue on the Basis of Positive Recommendation by IDMC

Oct 04, 2017

PharmaMar Submits the Marketing Authorisation Application for Aplidin® in Switzerland

Jun 20, 2017

FDA Chooses Zepsyre(TM) (PM1183) from PharmaMar to Explore Potential Development for Pediatric Cancers

Jun 16, 2017

PharmaMar Will Commercialize PM1183 With the Trade Name of Zepsyre(TM)